Rituximab More Effective Than Other MS Treatments? Rituximab More Effective Than Other MS Treatments?
Rituximab reduced relapses and MRI activity more effectively than dimethyl fumarate, natalizumab, and injectable therapies in a recent study. Disability did not differ between treatments, however.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 15, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

New four-year data show Roche's ENSPRYNG significantly reduces debilitating relapses in people with neuromyelitis optica spectrum disorder
Basel, 14 October 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new longer-term efficacy and safety data for ENSPRYNG® (satralizumab). The data show ENSPRYNG has a favourable benefit:risk profile and is effective in reducing relapses over four years of treatment in people with anti-aquaporin-4 antibody (AQP 4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD), a rare debilitating disease that affects the central nervous system. Efficacy and safety results from the open-label extension (OLE) periods of the SAkuraStar and SAkuraSky studies, in addition to the design of SAkuraBONSAI, a new ...
Source: Roche Media News - October 14, 2021 Category: Pharmaceuticals Source Type: news

New four-year data show Roche's ENSPRYNG significantly reduces debilitating relapses in people with neuromyelitis optica spectrum disorder
Basel, 14 October 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new longer-term efficacy and safety data for ENSPRYNG® (satralizumab). The data show ENSPRYNG has a favourable benefit:risk profile and is effective in reducing relapses over four years of treatment in people with anti-aquaporin-4 antibody (AQP 4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD), a rare debilitating disease that affects the central nervous system. Efficacy and safety results from the open-label extension (OLE) periods of the SAkuraStar and SAkuraSky studies, in addition to the design of SAkuraBONSAI, a new ...
Source: Roche Investor Update - October 14, 2021 Category: Pharmaceuticals Source Type: news

COVID-19 Vax in MS: Lower Response on Certain Medications COVID-19 Vax in MS: Lower Response on Certain Medications
New data on COVID vaccination in MS patients has shown a reduced humoral response in patients treated with certain medications -- including ocrelizumab, rituximab, and fingolimod -- but not others.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - October 14, 2021 Category: Infectious Diseases Tags: Neurology & Neurosurgery News Source Type: news

Clinical commissioning policy: Rituximab
This clinical commissioning policy sets out the criteria for Rituximab as a treatment option through routine commissioning for nodal/paranodal antibody positive inflammatory/autoimmune neuropathy in adults and postpubescent children. (Source: NHS Networks)
Source: NHS Networks - October 6, 2021 Category: UK Health Source Type: news

Roche to present new data on OCREVUS in multiple sclerosis and ENSPRYNG in neuromyelitis optica spectrum disorder at ECTRIMS 2021
Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS ® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) from 13 - 15 October 2021. These data include 38 abstracts highlighting new longer-term efficacy and safety for both OCREVUS and ENSPRYNG, as well as our ongoing efforts to evaluate the impact of the COVID-19 pandemic for people living with MS. Additional data will show how a deeper scientific understanding of MS and NMOSD in diverse patient populations ...
Source: Roche Investor Update - October 5, 2021 Category: Pharmaceuticals Source Type: news

Roche to present new data on OCREVUS in multiple sclerosis and ENSPRYNG in neuromyelitis optica spectrum disorder at ECTRIMS 2021
Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS ® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) from 13 - 15 October 2021. These data include 38 abstracts highlighting new longer-term efficacy and safety for both OCREVUS and ENSPRYNG, as well as our ongoing efforts to evaluate the impact of the COVID-19 pandemic for people living with MS. Additional data will show how a deeper scientific understanding of MS and NMOSD in diverse patient populations ...
Source: Roche Media News - October 5, 2021 Category: Pharmaceuticals Source Type: news

MS Treatment Choice May Influence Depression Risk MS Treatment Choice May Influence Depression Risk
Patients with MS who receive rituximab are 28% less likely to develop depression, compared with patients who receive interferons. Depression also may influence adherence to interferons.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 13, 2021 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Phase III study shows Roche's Polivy plus R-CHP is the first regimen in 20 years to significantly improve outcomes in previously untreated aggressive form of lymphoma compared to standard of care
Basel, 9 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the pivotal phase III POLARIX trial investigating Polivy ® (polatuzumab vedotin) in combination with MabThera®/Rituxan® (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) versus MabThera/Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), met its primary endpoint by demonstrating significantly improved an d clinically meaningful progression-free survival in people with previously untreated diffuse large B-cell lymphoma (DLBCL). Safety outcomes were consistent with those seen in previous...
Source: Roche Media News - August 9, 2021 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Phase III study shows Roche's Polivy plus R-CHP is the first regimen in 20 years to significantly improve outcomes in previously untreated aggressive form of lymphoma compared to standard of care
Basel, 9 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the pivotal phase III POLARIX trial investigating Polivy ® (polatuzumab vedotin) in combination with MabThera®/Rituxan® (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) versus MabThera/Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), met its primary endpoint by demonstrating significantly improved an d clinically meaningful progression-free survival in people with previously untreated diffuse large B-cell lymphoma (DLBCL). Safety outcomes were consistent with those seen in previous...
Source: Roche Investor Update - August 9, 2021 Category: Pharmaceuticals Source Type: news

FDA grants Breakthrough Therapy Designation for Venclexta in combination with azacitidine for the treatment of patients with myelodysplastic syndromes
Basel, 21 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Venclexta ® (venetoclax) in combination with azacitidine has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with previously untreated intermediate, high- and very high-risk myelodysplastic syndromes (MDS) based on the rev ised International Prognostic Scoring System (IPSS-R). MDS are a rare group of blood cancers that gradually affect the ability of the bone marrow to produce normal blood cells.2 This can lead to weakness, frequent infections, anaemia and ...
Source: Roche Media News - July 21, 2021 Category: Pharmaceuticals Source Type: news

FDA grants Breakthrough Therapy Designation for Venclexta in combination with azacitidine for the treatment of patients with myelodysplastic syndromes
Basel, 21 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Venclexta ® (venetoclax) in combination with azacitidine has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with previously untreated intermediate, high- and very high-risk myelodysplastic syndromes (MDS) based on the rev ised International Prognostic Scoring System (IPSS-R). MDS are a rare group of blood cancers that gradually affect the ability of the bone marrow to produce normal blood cells.2 This can lead to weakness, frequent infections, anaemia and ...
Source: Roche Investor Update - July 21, 2021 Category: Pharmaceuticals Source Type: news

Rituximab Seems Safe and Effective for Systemic Sclerosis Rituximab Seems Safe and Effective for Systemic Sclerosis
Rituximab seemed to be a safe and effective treatment for systemic sclerosis in a placebo-controlled validation trial in Japan.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 21, 2021 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Bayer-submits-regulatory-applications-oncology-treatment-combination-copanlisib-rituximab-US-EU
In the US, Bayer has filed for relapsed indolent B-cell non-Hodgkin’s lymphoma (B-iNHL) / In the EU, Bayer has filed for relapsed marginal zone lymphoma (MZL), a subtype of iNHL, and the filing has been accepted / Filings based on results from Phase III trial CHRONOS-3 showing a significant improvement in the primary endpoint of progression-free survival for the combination of copanlisib and rituximab in patients with relapsed iNHL (Source: Bayer Company News)
Source: Bayer Company News - June 21, 2021 Category: Pharmaceuticals Source Type: news

Rituximab Superior to Mycophenolate Mofetil in Pemphigus Vulgaris Study Rituximab Superior to Mycophenolate Mofetil in Pemphigus Vulgaris Study
Significantly more patients on rituximab achieved a complete sustained remission in the interim analysis of the trial, which enrolled 135 patients with moderate to severe pemphigus.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - June 12, 2021 Category: Dermatology Tags: Dermatology News Source Type: news

FDA approves ibrutinib plus rituximab for chronic lymphocytic leukemia
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Patients With RA on Rituximab at Risk for Worse COVID Outcomes Patients With RA on Rituximab at Risk for Worse COVID Outcomes
Risk mitigation strategies such as social distancing and wearing masks, especially indoors, remain important for people being treated with rituximab.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - June 8, 2021 Category: Rheumatology Tags: Rheumatology News Source Type: news

BEAT-LUPUS: Belimumab After Rituximab Delays Severe Flares BEAT-LUPUS: Belimumab After Rituximab Delays Severe Flares
Results from a phase 2b trial are"clearly encouraging" and"support the hypothesis that BAFF [B-cell-activating factor] can drive flares after rituximab," said Michael Ehrenstein, MD.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - June 4, 2021 Category: Dermatology Tags: Rheumatology News Source Type: news

Lower Steroid Dose Proves Effective for New-Onset ANCA Vasculitis Lower Steroid Dose Proves Effective for New-Onset ANCA Vasculitis
An open-label, randomized trial found that a reduced dose of glucocorticoids added to standard induction therapy with rituximab was safer and no worse than a higher dose at maintaining remission.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - June 1, 2021 Category: Drugs & Pharmacology Tags: Rheumatology News Source Type: news

COVID Vax Response Low in Immune-Mediated Inflammatory Diseases COVID Vax Response Low in Immune-Mediated Inflammatory Diseases
Patients who take methotrexate or rituximab seem to be especially vulnerable.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - May 26, 2021 Category: Infectious Diseases Tags: Rheumatology News Source Type: news

Rituximab, Mycophenolate Mofetil Compared for Pemphigus Vulgaris
WEDNESDAY, May 19, 2021 -- For patients with pemphigus vulgaris, rituximab is superior to mycophenolate mofetil for producing sustained complete remission at 52 weeks, according to a study published online May 19 in the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 19, 2021 Category: Pharmaceuticals Source Type: news

Antibiotic Cut ANCA-Vasculitis Infection Risk With Rituximab Antibiotic Cut ANCA-Vasculitis Infection Risk With Rituximab
Co-use of cotrimoxazole decreased the risk for infection, which remains high in patients with vasculitis who are treated with rituximab.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 7, 2021 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Rituximab Benefits Seen in Neuropsychiatric Lupus Rituximab Benefits Seen in Neuropsychiatric Lupus
Additionally, the use of concomitant cyclophosphamide might enhance the level of improvement seen in some patients, said Dr Trixy David in presenting data at the British Society for Rheumatology meeting.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - April 30, 2021 Category: Rheumatology Tags: Rheumatology News Source Type: news

Roche announces positive CHMP opinion for Venclyxto-based combinations in certain patients with acute myeloid leukaemia
Basel, 23 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Venclyxto® (venetoclax) in combination with a hypomethylating agent for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. Bas ed on this positive CHMP recommendation, a final decision regarding the approval of Venclyxto in certain patients with untreated AML is expected from the European Commission in the near future.“Today’s...
Source: Roche Investor Update - April 23, 2021 Category: Pharmaceuticals Source Type: news

Increased Risk for Infections in Children With Use of Rituximamb Increased Risk for Infections in Children With Use of Rituximamb
"Our study highlights a role for heightened vigilance of rituximab-associated hypogammaglobulinemia and infections in pediatric patients with rheumatic conditions," investigators concluded.Medscape Medical News (Source: Medscape Pediatrics Headlines)
Source: Medscape Pediatrics Headlines - April 20, 2021 Category: Pediatrics Tags: Rheumatology News Source Type: news

Vaccines Won ’t Protect Millions of Patients With Weakened Immune Systems
Many cannot produce enough infection-fighting cells to fend off the coronavirus. But researchers are testing one therapy that may help: monoclonal antibodies. (Source: NYT Health)
Source: NYT Health - April 16, 2021 Category: Consumer Health News Authors: Apoorva Mandavilli Tags: your-feed-science Antibodies Coronavirus (2019-nCoV) Vaccination and Immunization Immune System Drugs (Pharmaceuticals) Autoimmune Diseases Rituxan Leukemia & Lymphoma Society Regeneron Pharmaceuticals Inc Source Type: news

AACR: Copanlisib + Rituximab Slows Relapsed Indolent Lymphoma
Significant reduction found in risk for disease progression/death for C+R versus placebo and rituximab (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 13, 2021 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Conference News, Source Type: news

Combo Provides'Broad Benefit' Across NHL Subtypes Combo Provides'Broad Benefit' Across NHL Subtypes
The combination of copanlisib + rituximab led to a reduction in the risk for disease progression/death when compared with rituximab + placebo in patients with relapsed, indolent non-Hodgkin lymphoma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 13, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

AACR: Copanlisib + Rituximab Slows Relapsed Indolent Lymphoma
TUESDAY, April 13, 2021 -- Copanlisib plus rituximab (C+R) reduces disease progression or death in patients with relapsed indolent non-Hodgkin lymphoma (iNHL), according to a study presented during Week 1 of the annual meeting of the American... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 13, 2021 Category: Pharmaceuticals Source Type: news

FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
●  Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatmentBasel, 13 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. indications.1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic ...
Source: Roche Media News - April 13, 2021 Category: Pharmaceuticals Source Type: news

FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
●  Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatmentBasel, 13 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. indications.1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic ...
Source: Roche Investor Update - April 13, 2021 Category: Pharmaceuticals Source Type: news

Combination-copanlisib-rituximab-significantly-increases-progression-free-survival-patients-relapsed
Copanlisib is the first and only PI3K inhibitor to demonstrate broad and superior efficacy in combination with rituximab in patients with relapsed indolent non-Hodgkin’s Lymphoma (iNHL) compared to rituximab and placebo / Phase III trial CHRONOS-3 showed the combination of copanlisib and rituximab resulted in a 48% reduction in the risk of disease progression or death in patients with iNHL / The strong reduction in risk of progression or death was observed across all prespecified iNHL subtypes / The adverse event (AE) profile of the copanlisib and rituximab combination was manageable and generally consistent with pre...
Source: Bayer Company News - April 10, 2021 Category: Pharmaceuticals Source Type: news

Anti-CD20 Therapy for Lymphoma Tied to Worse COVID-19 Outcomes Anti-CD20 Therapy for Lymphoma Tied to Worse COVID-19 Outcomes
Lymphoma patients treated with B-cell-depleting anti-CD20 monoclonal antibodies, such as rituximab or obinutuzumab, may have worse outcomes from COVID-19 infection, according to a study from France.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 9, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Riabni (Rituximab-arrx Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 13, 2021 Category: Drugs & Pharmacology Source Type: news

FDA Approves Riabni (rituximab-arrx), a Biosimilar to Rituxan
THOUSAND OAKS, Calif., Dec. 17, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Riabni (rituximab-arrx), a biosimilar to Rituxan® (rituximab), for the treatment of adult... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 17, 2020 Category: Drugs & Pharmacology Source Type: news

New analysis method for predicting the risks and effects of immunotherapy
(Uppsala University) In a new study, researchers at Uppsala University have been able to show differences in how Rituximab, a monoclonal antibody drug, interacts with the blood of healthy individuals compared to patients with chronic lymphocytic leukaemia. This has awakened hopes that this analysis method could pave the way for important breakthroughs in immunotherapy research and treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 11, 2020 Category: International Medicine & Public Health Source Type: news

New data presented at ASH 2020 reinforces the benefit/risk profile of fixed-duration Polivy plus bendamustine and MabThera/Rituxan in patients with relapsed or refractory diffuse large B-cell lymphoma
Basel, 07 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced longer-term data from the pivotal phase Ib/II GO29365 study, including data from a single-arm extension cohort of 106 additional patients, which show the benefit of Polivy ® (polatuzumab vedotin) plus bendamustine and MabThera®/Rituxan® (rituximab) (BR) in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who are not eligible for stem cell transplant. Updated data from the randomised cohort (n=80) show that with longer follow-up (48.9 months) a complete response (CR) rate of 42.5% (n=17/40) was maintained ...
Source: Roche Media News - December 7, 2020 Category: Pharmaceuticals Source Type: news

New data presented at ASH 2020 reinforces the benefit/risk profile of fixed-duration Polivy plus bendamustine and MabThera/Rituxan in patients with relapsed or refractory diffuse large B-cell lymphoma
Basel, 07 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced longer-term data from the pivotal phase Ib/II GO29365 study, including data from a single-arm extension cohort of 106 additional patients, which show the benefit of Polivy ® (polatuzumab vedotin) plus bendamustine and MabThera®/Rituxan® (rituximab) (BR) in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who are not eligible for stem cell transplant. Updated data from the randomised cohort (n=80) show that with longer follow-up (48.9 months) a complete response (CR) rate of 42.5% (n=17/40) was maintained ...
Source: Roche Investor Update - December 7, 2020 Category: Pharmaceuticals Source Type: news

New follow-up phase III data reinforce the long-term benefit of Roche ’s Hemlibra for people with haemophilia A
Basel, 7 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from a new analysis of pooled, three-year follow-up data of 401 people with haemophilia A from the pivotal HAVEN 1-4 studies, which reinforce the long-term efficacy and safety profile of Hemlibra ® (emicizumab).[1]These data, from adults, adolescents and children with haemophilia A with and without factor VIII inhibitors, were presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 5-8 December 2020.“The long-term benefit of Hemlibra, with a consistent safety profile and durably effect...
Source: Roche Media News - December 7, 2020 Category: Pharmaceuticals Source Type: news

New follow-up phase III data reinforce the long-term benefit of Roche ’s Hemlibra for people with haemophilia A
Basel, 7 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from a new analysis of pooled, three-year follow-up data of 401 people with haemophilia A from the pivotal HAVEN 1-4 studies, which reinforce the long-term efficacy and safety profile of Hemlibra ® (emicizumab).[1]These data, from adults, adolescents and children with haemophilia A with and without factor VIII inhibitors, were presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 5-8 December 2020.“The long-term benefit of Hemlibra, with a consistent safety profile and durably effect...
Source: Roche Investor Update - December 7, 2020 Category: Pharmaceuticals Source Type: news

New Data Demonstrate Long-Term Benefit of IMBRUVICA ® (ibrutinib) as First-Line Treatment for High-Risk Chronic Lymphocytic Leukemia
This study highlighted the need for cytogenetic/molecular testing before CIT treatment, consistent with clinical treatment guidelines.[8],[9]Real-World Prognostic Biomarker Testing, Treatment Patterns, And Dosing Among Patients With CLL/SLL From the informCLL™ Prospective Observational Registry (Abstract #547)An oral presentation on Monday, December 7, will feature results from the informCLL™ real-world prospective observational registry assessing treatment patterns in the era of novel agents.4 Key Study Findings:· The most common index treatment was IMBRUVICA®; the majority of patients treated with ...
Source: Johnson and Johnson - December 6, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Roche announces new data reinforcing the long-term benefit of Venclexta/Venclyxto-based combination for people with relapsed or refractory chronic lymphocytic leukaemia
             Basel, 5 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from the pivotal phase III MURANO and CLL14 studies support the efficacy of fixed-duration, chemotherapy-free Venclexta ®/Venclyxto® (venetoclax)-based combinations in certain people with chronic lymphocytic leukaemia (CLL) and provide more evidence on the potential value of minimal residual disease (MRD). Data were presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition on Saturday 5 December 2020.“...
Source: Roche Media News - December 5, 2020 Category: Pharmaceuticals Source Type: news

Roche announces new data reinforcing the long-term benefit of Venclexta/Venclyxto-based combination for people with relapsed or refractory chronic lymphocytic leukaemia
             Basel, 5 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from the pivotal phase III MURANO and CLL14 studies support the efficacy of fixed-duration, chemotherapy-free Venclexta ®/Venclyxto® (venetoclax)-based combinations in certain people with chronic lymphocytic leukaemia (CLL) and provide more evidence on the potential value of minimal residual disease (MRD). Data were presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition on Saturday 5 December 2020.“...
Source: Roche Investor Update - December 5, 2020 Category: Pharmaceuticals Source Type: news

Disease-Free Survival Data from CAPTIVATE Study Demonstrate Benefit of IMBRUVICA ® (ibrutinib)-Based Regimen as Fixed Duration, First-Line Treatment for Patients with Chronic Lymphocytic Leukemia
December 5, 2020 (RARITAN, N.J.) – New data from the Phase 2 CAPTIVATE study were presented today during an oral session at the 2020 American Society of Hematology (ASH) Annual Meeting (Abstract #123). The study evaluated the efficacy and safety of IMBRUVICA® (ibrutinib) plus venetoclax in the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and showed that, after achieving undetectable minimal residual disease (uMRD) in both the blood and bone marrow with the IMBRUVICA® combination regimen, the one-year disease-free survival (DFS) of patients randomized ...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA approves Xolair ® (omalizumab) for adults with nasal polyps
             Basel, 01 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.1 Nasal polyps can lead to a loss of smell and nasal congestion, and frequently co-occur with other respiratory conditions, such as allergies and asthma. With this ap...
Source: Roche Media News - December 1, 2020 Category: Pharmaceuticals Source Type: news

FDA approves Xolair ® (omalizumab) for adults with nasal polyps
             Basel, 01 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.1 Nasal polyps can lead to a loss of smell and nasal congestion, and frequently co-occur with other respiratory conditions, such as allergies and asthma. With this ap...
Source: Roche Investor Update - December 1, 2020 Category: Pharmaceuticals Source Type: news

Janssen Headlines American Society of Hematology Annual Meeting With More Than 35 Presentations Highlighting Deep, Diverse Oncology Pipeline and Portfolio
RARITAN, N.J., November 5, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today more than 35 company-sponsored studies, including 10 oral presentations, will be featured at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually December 5-8, 2020.In multiple myeloma, highlights include Phase 1b/2 results for the B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy ciltacabtagene autoleucel (cilta-cel); new and updated data for the anti-CD38 monoclonal antibody DARZALEX® (daratumumab) and the subcutane...
Source: Johnson and Johnson - November 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

14.10.20: Not intended for U.S. and UK Media
Combination of copanlisib and rituximab significantly prolonged progression-free survival of patients with relapsed indolent non-Hodgkin's LymphomaPhase III study CHRONOS-3 in patients with relapsed indolent non-Hodgkin's Lymphoma (iNHL) who have received one or more lines of prior treatment meets primary endpoint / Safety and tolerability observed in the trial were generally consistent with previously published data on the individual components of the combination and no new safety signals were identified / Copanlisib is already approved in the U.S. under accelerated approval based on overall response rate (ORR) of 104 adu...
Source: Bayer IR Newsfeed: Events - October 14, 2020 Category: Pharmaceuticals Source Type: news

Innovent and Lilly Jointly Announce the NMPA Granted Marketing Approval for HALPRYZA(R) (Rituximab Injection) in China
SAN FRANCISCO and SUZHOU, China, Oct. 9, 2020 -- (Healthcare Sales & Marketing Network) -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... Biopharmaceuticals, Oncology, Regulatory Innovent Biologics, Eli Lilly, HALPRYZA, rituximab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 9, 2020 Category: Pharmaceuticals Source Type: news

Novel Radioimmunotherapy Reverses Resistance to Commonly Used Lymphoma Drug
(Society of Nuclear Medicine and Molecular Imaging) A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab, according to research published in the October issue of The Journal of Nuclear Medicine. When used in combination with rituximab, 177Lu-lilotomab-satetraxetan was shown to substantially increase rituximab binding and rituximab-mediated antibody-dependent cellular cytotoxicity (ADCC) activity, resulting in significant tumor growth delay in a non-Hodgkin's lymphoma mouse model. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 8, 2020 Category: Cancer & Oncology Source Type: news